The first domestic teriflunomide tablets were sold on the market, and the drug security for rare diseases ushered in new hope

Categories:Company News
Author:
Origin:
Time of issue:2022-08-10
Views:0

(Summary description)Today, the first domestic teriflunomide tablets developed by Shengshi Tyco are on sale. The first batch of patients will benefit Beijing, Shanghai, Guangzhou, Chengdu, Suzhou and other core cities. The follow-up will soon cover the national market, bringing new choices and drug supply guarantees for domestic patients with multiple sclerosis.

The first domestic teriflunomide tablets were sold on the market, and the drug security for rare diseases ushered in new hope

(Summary description)Today, the first domestic teriflunomide tablets developed by Shengshi Tyco are on sale. The first batch of patients will benefit Beijing, Shanghai, Guangzhou, Chengdu, Suzhou and other core cities. The follow-up will soon cover the national market, bringing new choices and drug supply guarantees for domestic patients with multiple sclerosis.

Categories:Company News
Author:
Origin:
Time of issue:2022-08-10
Views:0

Today, the first domestic teriflunomide tablets developed by CGeneTech are on sale. The first batch of patients will benefit Beijing, Shanghai, Guangzhou, Chengdu, Suzhou and other core cities. The follow-up will soon cover the national market, bringing new choices and drug supply guarantees for domestic patients with multiple sclerosis.

Multiple sclerosis (MS) is a lifelong, chronic and progressive disease. More than 2.3 million people worldwide suffer from multiple sclerosis, and nearly 50000 patients in China. In May 2018, multiple sclerosis was included in the first list of rare diseases in China. Its etiology originates from the pathological changes of the autoimmune system, causing the damage and peeling of the nerve myelin sheath, resulting in the damage of the spinal cord, brain and optic nerve functions. The patient's nervous system disability gradually worsens, and the patient loses self-care ability, blindness and even life. Early diagnosis and treatment are required.

Teriflunomide is an immune modulator with anti-inflammatory effect. It has definite efficacy and good safety when taken for a long time. It is the first-line drug recommended by domestic and foreign guidelines for the treatment of multiple sclerosis. The telifloxamine tablets developed by CGeneTech passed the consistency evaluation with the original drugs. The marketing broke the current situation of excessive dependence on imported drugs for the treatment of multiple sclerosis. It will significantly improve the drug availability of domestic patients, ensure the continuity of drug supply, and not be affected by various overseas factors.

Dr. Yu Qiang, founder and CEO of CGeneTech, said: "In fact, rare diseases are not rare. But there is no medicine to cure, which is the unspeakable pain of patients with rare diseases. The earlier the diagnosis and treatment of multiple sclerosis are, the better the symptoms can be alleviated and the development of the disease can be delayed. Therefore, today we are glad to see that the terfloxacin tablets produced by CGeneTech are sold on the market, benefiting domestic patients and making every small group no longer give up. In the future, the company will focus on the unmet needs of China and the world Guided by clinical needs, we will develop innovative drugs with high accessibility and better efficacy to benefit patients worldwide. "

Founded in Suzhou Industrial Park in 2010, CGeneTech is committed to the R & D and industrialization of small molecule innovative drugs for breakthrough therapies. Relying on the integrated drug R & D technology platform and diversified business vision, the company has built a rich pipeline of innovative drugs, covering many disease fields such as glucose lowering, anticancer and rare diseases. Among them, the original hypoglycemic new drug Cetagliptin phosphate has entered the final stage of clinical phase III, which is expected to fill the gap of domestic original DPP-4 inhibitors; Three of the anticancer drugs under research have entered the clinic. The FGFR / VEGFR dual target inhibitor cgt-6321 has been carried out in phase I clinical trials in advanced solid tumors, and this drug is expected to become a potential first in class drug; CXCR4 antagonist cgt-1881 is used for hematopoietic stem cell mobilization, and oral administration is more convenient; Cgt-9475, a new generation ALK / ret inhibitor, is expected to solve several major clinical pain points such as drug resistance and brain metastasis in the treatment of lung cancer. Both of the latter two projects have obtained the clinical approval of the US FDA, which has taken a solid step in the company's innovative drugs going to sea.

Previous: Dr. Wang Tong: Pursue the "Star Sea" of Drug Research and Development from Fragment Molecular Library

Next: China and the United States reported that the new generation of ALK inhibitor of CGeneTech was approved for clinical use in the United States

Previous: Dr. Wang Tong: Pursue the "Star Sea" of Drug Research and Development from Fragment Molecular Library

Next: China and the United States reported that the new generation of ALK inhibitor of CGeneTech was approved for clinical use in the United States

Shengshi Taike: Exchange 'One Promise, One Thousand Gold' for 'Dreams Come True'

Introduction: Adhere to our original aspiration, forge ahead, and let our dreams shine into reality. The rapid development of Suzhou Industrial Park is the result of generations of park residents' continuous efforts, and also embodies the strength of each enterprise's rooting and growth. Enterprises are witnesses, but also participants. In the park, one group after another of enterprises have run the "upward trend" with their own "hard skills", using abundant vitality as ink and strong resilience as pen, writing a wonderful chapter of "striving for thirty years and building dreams towards the future". On the occasion of 15 years of rooting in Suzhou Industrial Park, Shengshi Taike Biopharmaceutical Technology (Suzhou) Co., Ltd. has reached a major development milestone - the company's first independently developed Class 1 innovative drug, sitagliptin phosphate tablets, has been approved for listing in China. The founder and CEO of Shengshi Taike, Yu Qiang, wrote a poem with deep emotion: "The trees and trees are all singing in heaven, and the colors are shining in the hall. The morning sun shines on the clouds, and the prosperous era welcomes the sunrise The original intention of entrepreneurship and the passion for innovation are intertwined at this moment into a beautiful story of the "two-way rush" between the park and talents. The successful approval of sengliptin for listing is due to the entrepreneurial fertile ground of Suzhou and the park, as well as the strong support of many departments. It is also a way to repay the park's pro business services with our innovative drugs, "said Yu Qiang. Since settling in the park in 2010, Shengshi Taike has been based in Suzhou and has a global perspective, focusing on the research and production of small molecule innovative drugs. With an integrated drug research and development technology platform and diversified business vision, it has built a rich pipeline of innovative drugs covering areas such as blood sugar reduction, anti-cancer, and autoimmune。 Funds - the 'first pot of gold' that leverages innovation leverage In 2010, with rich scientific research and practical experience in the field of pharmaceutical research and development, Yu Qiang and partner Ding Juping established Shengshi Taike in Suzhou Biomedical Industry Park (BioBAY), committed to the research and industrialization of breakthrough small molecule innovative drugs for therapeutic purposes. "China is a big country with diabetes in the world, and the number of patients with diabetes is the first in the world. In 2008, I heard the news that China began to attach importance to the biomedical industry. Around 2010, I decided to bring my initial research and development achievements, raise funds, form a team, and return to China to make a new class of hypoglycemic drugs." Recalling more than a decade ago, Yu Qiang still remembers. The decision to return to China and start a business in the park was impressed by the numerous emails exchanged. At that time, I was still in the United States and consulted the park government about entrepreneurship issues through email. The response I received was not only fluent in English, but also highly professional. The fact has proven that my initial choice was the right one The beginning of everything is difficult. Even if the conditions for starting a business in China are relatively mature, for a new drug research and development company in the start-up stage, the challenges it faces can be imagined. Shortage of funds is the first problem. Fortunately, the park provides very strong financial support to leading talents, "said Yu Qiang. When he settled in 2010, the park could offer a" big gift package "of up to 10 million yuan to leading talents in the biopharmaceutical field, including housing subsidies, rent reductions, subsidized loans, start-up capital, etc. More importantly, the predecessor of Yuanhe Holdings, Zhongxin Venture Capital, gave us 6.5 million yuan in angel investment, which can be said to be a" timely help "for start-up companies. Later, the company's new drugs were successively shortlisted for the national "Twelfth Five Year Plan", "Thirteenth Five Year Plan" and "Major New Drug Creation" special projects, and were included in the national key support track, further obtaining financial support. The guidance fund and leading venture capital of the park's enterprise development service center have provided financing support at different stages of Shengshi Taike's development. With the guidance of government industry funds, they have also attracted more social capital to invest and jointly support enterprise innovation. I have always believed that it is the '1' given by the park that leads to the '0' increase in social capital in the future, "Yu Qiang said with a smile. Funds support the growth of enterprises and drive industrial development. At present, Shengshi Taike has built a rich drug pipeline, with product distribution fr

2025-01-07

Milestones | Shengshi Taike's new generation DPP-4 inhibitor approved for market launch

Today, the official website of the National Medical Products Administration (NMPA) of China announced that Shengshi Taike's independently developed Class 1 innovative drug, saxagliptin phosphate tablets (formerly known as saxagliptin phosphate tablets), has been approved for market in China. This is a new generation of highly selective DPP-4 inhibitor, which is suitable for improving the blood sugar control of adult type 2 diabetes patients. According to the Guidelines for the Prevention and Treatment of Type 2 diabetes in China, the prevalence of diabetes among adults in China has risen to 11.2%, of which more than 90% are type 2 diabetes. In order to meet the huge clinical demand, some new drugs with different mechanisms of action from traditional oral hypoglycemic drugs have emerged in recent years. Dipeptidyl peptidase-4 (DPP-4) inhibitors are one of them. They not only improve hyperglycemia, but also are not easy to induce hypoglycemia and weight gain. They have the characteristics of rapid oral absorption, long half-life, and long-lasting effect, and are known as "smart" hypoglycemic drugs. Currently, they have been recommended by many domestic and foreign guidelines. As a new generation of highly selective DPP-4 inhibitor independently developed by Shengshi Taike, sengliptin has been continuously selected for the national "Major New Drug Development" special projects in the 12th and 13th Five Year Plans. Due to the excellent data demonstrated in the first phase clinical trial of the best product in the market, it was exempted from phase 2 clinical trials and directly entered phase 3 clinical trials, pioneering the "exemption from two to three" clinical trials in the field of this drug. The results of the phase III clinical trial of Sengliptin led by Professor Ji Linong, director of the Endocrinology Department of Peking University People's Hospital and director of Peking University diabetes Center, showed that in the single drug treatment trial of Sengliptin, the reduction values of HbA1c in the 50mg and 100mg dose groups at the end of the 24th week were 1.08% and 1.07% respectively; In the treatment trial of sengliptin combined with metformin, the glycated hemoglobin decreased by 1.23% and 1.17% in the 50mg and 100mg dose groups at the end of the 24th week, respectively. Meanwhile, both sets of experimental data showed that patients with higher blood sugar levels experienced a greater decrease in glycated hemoglobin levels. In addition to its excellent hypoglycemic effect, what is even more commendable is that in the comparison between the 100mg dose group (high-dose group) and the placebo group in the last 28 weeks, the incidence of adverse reactions of sengliptin is similar to that of the placebo group, and its safety further solves the common adverse reactions in marketed products. At present, metformin combined with leptin has become the main treatment scheme in the clinical application of treating type 2 diabetes. According to Sullivan's research report, by 2030, the market size of leptin in China will exceed 30 billion, with broad market prospects. Ding Juping, the co-founder and president of Shengshi Tyco, said: "I am very glad to see the company's self-developed product, Sengliptin Phosphate Tablets, has been approved for listing. This drug will be the best new hypoglycemic drug of its kind with half the effort and twice the treatment effect. I hope it will benefit the majority of diabetes patients in China as soon as possible after it is approved for listing." Dr. Yu Qiang, the founder and CEO of Shengshi Tyco, said: "Sengliptin's successful approval for listing benefits from Suzhou and the park as a fertile land for entrepreneurship and the strong support of many departments. It is also a" promise of gold "to use our innovative drugs to repay the business friendly services in Suzhou Park. At this moment, I would like to use an original poem to bless this new drug for its successful launch." Morimu's sounds of nature are listed in the palace. The morning light shines on the clouds, and the prosperous world welcomes the sunrise.

2024-12-05